anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide the subject new compound having excellent antibacterial activity and low toxicity and useful as an active component of antibacterial agent for the prevention and treatment of various infectious diseases. CONSTITUTION:The quinolinecarboxylic acid derivative of formula I [Z is group of formula II, formula III (R<1> is H, halogen, etc.), etc.] or its salt, e.g. 9,1-(methylimino)methano-7-fluoro-8-(2-methylmorpholino)-5-oxo-5H-thia zolo[3,2- a]quinoline-4-carboxylic acid. The compound can be produced by reacting a quinolinecarboxylic acid derivative of formula IV (R is H, lower alkyl, etc.) with a cyclic amine of formula ZH or its acid addition salt generally at a temperature between room temperature and 150 deg.C and, as necessary, hydrolyzing the product. The reaction of the compound of formula II with the amine of formula ZH is preferably carried out in a polar organic solvent (e.g. dimethyl sulfoxide) in the presence of an acid acceptor (e.g. triethylamine).
A system and method for allowing a user to create and edit a charge capture slip on an electronic device. The disclosure is suited for use on mobile, touch-sensitive electronic devices. A template screen is presented to a user with medical procedure codes, diagnosis codes, and a summary viewable simultaneously. The user can select codes to add to the summary and can also create customized templates. The user is presented with a multitude of options when viewing a created charge capture slip. The user can delete, modify, and multiply codes. The user can reposition a procedure code on the charge capture slip, while diagnosis codes associated with that procedure code are automatically also repositioned so as to maintain their relationship with the procedure code.
Compositions, which are stable in storage, and a method of production of pharmaceutical based nanoparticutate formulations for clinical use in photodynamic therapy comprising a hydrophobic photosensitizer, poly(lactic-co-glycolic) acid and stabilizing agents are provided. These nanoparticulate pharmaceutical formulations provide therapeutically effective amounts of photosensitizer for parenteral administration. In particular, tetrapyrrole derivatives can be used as photosensitizers, whose efficacy and safety are enhanced by such nanoparticulate formulations. It also leaches the method of preparing PLGA-based nanoparticles under sterile conditions. In one of the preferred embodiments of the present invention PLGA-based nanoparticles have a mean particle size less than 500nm and the photosensitizer is temoporf n, 5,10,15,20-tetrakis(3-hydroxyphenyl)-chlorin (mTHPC).; In another embodiment, the photosensitizer 2,3-dihydroxy-5,10,15,20-tetrakis(3- hydroxyphenyl)-chlorin (mTHPD-OH) is formulated as a nanoparticle for parenteral administration. Yet, in another embodiment preferred photosensitizer is 5,10,15,20-tetrakis(3- hydroxyphenyl)-porphyrin (mTHPP). The formulations can be used for treating hyperptasic and neoplasia conditions, inflammatory problems, and more specifically to target tumor cells.
Testosterone deficiency has been recognized as a significant health concern and is closely related to obesity. The weight-adjusted-waist index (WWI) is an innovative adiposity parameter that is superior to BMI in certain aspects, but its relationship with testosterone levels has not been elucidated. The aim of this study was to investigate the relationships of the WWI with total testosterone levels and testosterone deficiency. Data from the National Health and Nutrition Examination Survey (NHANES, 2011-2016) were utilized. The WWI was calculated as waist circumference (cm) over the square root of weight (kg), and a total testosterone level of less than 300 ng/dL was defined as testosterone deficiency. Weighted multivariable regression models were used to assess the associations. A total of 6859 participants were included, 26.28% of whom were testosterone deficient. The WWI was inversely related to total testosterone levels (β = -49.93, 95% CI: -60.07, -39.78, P < 0.001) and positively associated with testosterone deficiency (OR = 1.46, 95% CI: 1.23, 1.72, P < 0.001) in the fully adjusted model. A significant nonlinear relationship was also detected between WWI and testosterone deficiency (P for nonlinearity = 0.004) with an inflection point of 9.486 cm/√kg. The associations were consistent in the subgroup analysis (all P > 0.05), except for the participants with eGFR < 60 mL/(min*1.73m2) and hypertension. A higher WWI was linked to lower total testosterone levels and a greater risk of developing testosterone deficiency, especially among those who had an eGFR ≥ 60 mL/(min*1.73m2) and were nonhypertensive.
FIELD: medicine, pharmacy. SUBSTANCE: preparation has 2-[(2-pyridyl)-methylsulfinyl] -benzimidazole derivative or its salt that shows antiulcer activity at the dose 0.05-10 mg/ml as measured for free base. Preparation has also alkali and an aqueous solvent without addition of nonaqueous solvent, pH value of preparation for injection is at least 9.5 but not above 11.5. A set for injection has a lyophilized product of an alkaline hydrolysis of solution of 2-[(2-pyridyl)-methylsulfinyl]-benzimidazole compound or its salt and an aqueous solvent. The indicated components are taken at ratios to provide pH 9.5-11.5. New injection preparation ensures to avoid pH value decrease for hemolysis prevention and local irritation and addition of nonaqueous solvent to an aqueous solvent to provide dissolution and prevention of a solvent solubility decrease. EFFECT: improved quality of a preparation. 5 cl, 1 tbl, 1 ex
RNA polymerase I transcription in vivo in transiently DNA-transfected cells has been used for expression of influenza vRNA molecules coding for chloramphenicol acetyltransferase (CAT) in anti-sense orientation. Influenza virus superinfection served to provide viral RNA polymerase and other proteins for transcriptional conversion of minus-strand vRNA into plus-strand viral mRNA molecules expressing CAT activity. This system has been used for an analysis via nucleotide exchanges as well as deletions and insertions of both terminal segments of the vRNA sequence which cooperatively constitute the vRNA promoter structure. Several mutants with greatly enhanced expression rates over wild-type levels have been constructed, which also can be packaged and serially passaged into progeny virus. The data obtained for the mutations in various promoter elements support a model of consecutive, doublestrand vRNA promoter structures in binding of viral polymerase and initiation of RNA synthesis. Preparations of attenuated influenza virus for vaccination purposes include a single recombinant segment with promoter up mutation(s) for over-expression of an own or foreign gene product, which at the same time because of its over-replication serves to decrease the number of helper virus RNP segments. The same viruses further have been passaged through a step of ribozyme cleavage acting at one of the helper viral segments, which will delete this vital function and structure with high rates from the virus progeny. The resulting attenuated viruses will interact with their target cells in only one round of abortive infection, and are unable to produce viral progeny.
The invention discloses a cleaning-free medical ultrasonic couplant, and a preparation method thereof. The medical ultrasonic couplant comprises 0.1 to 2% by mass of water-soluble polymer materials, 5 to 30% by mass of volatile components, 0.2 to 2% by mass of skin moisturizing and protecting components, 0.05 to 5% by mass of sterilization components, a pH regulating component and deionized water. The medical ultrasonic couplant can form a thin film on patient skin and requires no cleaning, is safe for patient skin and does not contaminate clothes. Through utilizing the medical ultrasonic couplant, the advantages of simplifying ultrasonic detection processes, saving ultrasonic detection time, saving cleaning paper, reducing dust resulting from cleaning paper, and improving greatly an ultrasonic detection environment and the cleaning and maintenance of ultrasonic instruments. A viscosity of the medical ultrasonic couplant is controlled within a range of 3000 to 12000 centipoises and thus the medical ultrasonic couplant is a couplant with a medium to low viscosity and can be utilized by a spray way. Therefore, compared with the existing high viscosity couplant which is utilized by an extrusion way, the medical ultrasonic couplant provided by the invention is more convenient.
This is a trial with an observational and an interventional arm, in patients with moderate to severe anemia and control subjects. The main purposes of this study is to phenotype the scope of neurocognitive deficits from iron deficiency anemia (IDA) in adult women, determine derangements in cerebral perfusion, vascular reactivity, functional connectivity, and blood brain barrier permeability in adult-onset IDA and relate them to neurocognitive deficits, as well as determine the reversibility and durability of both the physiologic and neurocognitive derangements by iron replacement therapy. All eligible subjects will be asked to provide informed consent before participating in the study.

Comprehensive cerebrovascular magnetic resonance imaging (MRI), bloodwork, patient reported outcomes, and neurocognitive testing will be collected from all subjects in the observational arm. 136 subjects total will be enrolled, 40 controls and 96 anemic subjects. The 96 eligible anemic subjects will then be invited to enroll in the interventional arm of the study. Anticipating a drop-out rate of 20%, 40 will be randomized into intravenous iron therapy, and 40 will be randomized into standard of care (oral iron via primary care). Repeated tests will be done at different timepoints to assess the effects and durability of iron therapy.
The present invention relates to calcium brown rice using Fomes fomentarius Fr. and to a manufacturing method thereof. More specifically, the manufacturing method comprises the following steps: washing and drying brown rice; coating the washed and dried brown ice with a coating solution; and drying the coated brown rice. The coating solution includes a Fomes fomentarius Fr. concentrate, seaweed calcium, vitamin D3 powder, and fish collagen powder. The Fomes fomentarius Fr. concentrate is acquired by concentrating a hot water extract of Fomes fomentarius Fr. According to the present invention, digestion and an adsorption rate of brown rice are enhanced; and nutrients, such as organic germanium, calcium, collagen, etc., which are difficult to be easily taken in an ordinary diet, are efficiently taken and adsorbed. Moreover, sensory and storage properties of brown rice can be improved.
FIELD: chemistry. ^ SUBSTANCE: oral administration form contains at least one type of probiotic microorganisms and a coating which includes at least two cellulose esters, preferably hydroxypropylmethylcellulose and hydroxyproylcellulose. One of the esters exclusively contains hydroxyalkyl groups as ester substitutes, and the second contains alkyl groups as ester substitutes, besides hydroxyalkyl groups. The said coating is prepared in an aqueous solution or in a water-alcohol solution. ^ EFFECT: provision for high activity of probiotic microorganisms in the intestines, as well as longer shelf-life of the form. ^ 11 cl, 8 ex
In this arm the participants will be treated with Vitamin D. The participants will be prescribed a dose of 1000 IU a day (1 pill a day). At 6 weeks the dosage will increase to 2000 IU a day (2 pills a day).
Chronic pain after mastectomy, or breast tissue removal, is very common with almost half of women experiencing some type of residual pain and even 13% characterizing it as severe. Poor acute postoperative pain control is not only associated with development of chronic pain, but has also been shown to be associated with delayed wound healing. Therefore, optimization of postoperative pain control is paramount not just for patient comfort, but to decrease immediate and long-term postoperative complications.

There are two adjunctive modes of perioperative pain control currently in use at Columbia University Medical Center (CUMC). The first mode uses pulsed electromagnetic fields (PEMF) and consists of a noninvasive device placed over dressings around the surgical site. The second is a regional anesthetic and -the pectoral interfascial block (PIB) in which a long-lasting local anesthetic (bupivacaine/ropivacaine) is injected into the surgical dissection area. Both of these techniques for postoperative analgesia have been shown to be effective in different types of breast surgery, but there is no current literature comparing the two modalities in their efficacy in reducing postoperative pain. There is also no current literature in their efficacy in the mastectomy and tissue expander patient population. The proposed trial is a prospective, randomized, controlled, double-blind trial to evaluate the efficacy of these two modalities of postoperative analgesia in patients undergoing mastectomy and tissue expander reconstruction.
###  Cardiac Failure

Sympathetic stimulation is a vital component supporting circulatory function, and beta blockade carries the potential hazard of depressing myocardial contractility and precipitating or exacerbating minimal cardiac failure. 

During treatment with metoprolol, the hemodynamic status of the patient should be carefully monitored. If heart failure occurs or persists despite appropriate treatment, metoprolol should be discontinued.

###  Bradycardia

Metoprolol produces a decrease in sinus heart rate in most patients; this decrease is greatest among patients with high initial heart rates and least among patients with low initial heart rates. Acute myocardial infarction (particularly inferior infarction) may in itself produce significant lowering of the sinus rate. If the sinus rate decreases to < 40 beats/min, particularly if associated with evidence of lowered cardiac output, atropine (0.25 to 0.5 mg) should be administered intravenously. If treatment with atropine is not successful, metoprolol should be discontinued, and cautious administration of isoproterenol or installation of a cardiac pacemaker should be considered.

###  AV Block

Metoprolol slows AV conduction and may produce significant first- (P-R interval ≥ 0.26 sec), second-, or third-degree heart block. Acute myocardial infarction also produces heart block. 

If heart block occurs, metoprolol should be discontinued and atropine (0.25 to 0.5 mg) should be administered intravenously. If treatment with atropine is not successful, cautious administration of isoproterenol or installation of a cardiac pacemaker should be considered.

###  Hypotension

If hypotension (systolic blood pressure ≤ 90 mmHg) occurs, metoprolol should be discontinued, and the hemodynamic status of the patient and the extent of myocardial damage carefully assessed. Invasive monitoring of central venous, pulmonary capillary wedge, and arterial pressures may be required. Appropriate therapy with fluids, positive inotropic agents, balloon counterpulsation, or other treatment modalities should be instituted. If hypotension is associated with sinus bradycardia or AV block, treatment should be directed at reversing these (see above).

Bronchospastic Diseases:  PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD, IN GENERAL, NOT RECEIVE BETA BLOCKERS, including Metoprolol tartrate. Because of its relative beta1 selectivity, metoprolol may be used with extreme caution in patients with bronchospastic disease. Because it is unknown to what extent beta2-stimulating agents may exacerbate myocardial ischemia and the extent of infarction, these agents should not be used prophylactically. If bronchospasm not related to congestive heart failure occurs, metoprolol should be discontinued. A theophylline derivative or a beta2 agonist may be administered cautiously, depending on the clinical condition of the patient. Both theophylline derivatives and beta2 agonists may produce serious cardiac arrhythmias.
Patients receive mitotane PO daily on days 1-21. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
INTRODUCTION: People with HIV (PWH) have nearly twice the risk of emphysema than people without HIV. This risk, which has been associated with HIV-mediated changes in the lung immune environment and more extensive radiographic emphysema, may result in different patterns of airflow limitation on pulmonary function testing (PFT) than those traditionally used in people without HIV.
METHODS: In this prospective cohort of PWH in Atlanta, Georgia, we analyzed PFT and chest computed tomography data from July 2013 through June 2018. After comparing the prevalence of PFT measures of airflow limitation for those with and without radiographic emphysema, we used binary recursive partitioning to identify PFT measures that differentiated between PWH with and without radiographic emphysema.
RESULTS: Among 167 PWH who had both PFT and computed tomography data during the study period, 89 (53%) had radiographic emphysema. Those with radiographic emphysema were more likely to have airflow limitations on PFTs. Recursive partitioning identified partitions at a forced expiratory volume in 1 second to forced vital capacity ratio (FEV1/FVC) of 0.78 and a residual volume of 116% predicted. These partitions enabled the identification of 84 (94%) PWH with radiographic emphysema, in contrast to the traditional diagnostic criteria of an FEV1/FVC ratio of 0.7, which only identified 49 (55%) of those with radiographic emphysema.
CONCLUSIONS: Emphysema in PWH may have different patterns of airflow limitation on PFTs that are not adequately captured by traditional diagnostic criteria. Future studies can seek to validate these findings and determine optimal thresholds for diagnosing HIV-associated emphysema.
This study is a long-term prospective, single-blind study comparing biofeedback for pelvic floor dyssynergia to a skeletal muscle relaxant drug (diazepam 5 mg two hours before attempted defecation) and to placebo medication. Prior to randomization, patients will first receive medical therapy (laxatives and education) for 4 weeks and only those remaining constipated will be randomized. Physiological tests of anal canal pressure during straining to defecate and ability to pass a 50-ml air filled balloon will be tested before and after treatment. Patients will keep a diary throughout baseline and treatment, and they will be reassessed at 3, 6, and 12 months follow-up. Treatment will consist of 6 clinic visits at 2-week intervals. The investigators will develop a detailed treatment manual for this disorder which would permit other investigators to replicate their study.
A compact, single use pad applicator is disclosed having a dry medication (e.g. a dehydrated topical astringent disinfectant that is adapted to treat acne and has been reduced to crystalline form by lyophilization) stored in a first chamber. A liquid diluent is stored in a second chamber. Fluid communication between the first and second chambers is blocked by a normally closed, pressure activated valve or seal. By compressing the second chamber, a corresponding hydraulic pressure is generated in the diluent which opens the valve. Accordingly, the diluent in the second chamber is introduced under pressure to the dry medication in the first chamber to rehydrate and activate the acne medication. The reconstituted multi-constituent liquid medication is absorbed by a pad-shaped swab so as to be applied directly to a relatively wide tissue area as a topical treatment for acne or other skin disorders.
1,248,070. Thiazolylbenzoic acids. SCIENCE UNION ET CIE SOC. FRANCAISE DE RECHERCHE MEDICALE. 15 Dec., 1969 [16 Dec., 1969], No. 59720/68. Heading C2C. Novel thiazolylbenzoic acids of the general formula wherein R 1  is a hydrogen atom or a C 1-5  alkyl group, R 2  is a C 1-5  alkyl or phenylalkyl group or a phenyl group optionally substituted by one or more halogen atoms or C 1-5  alkyl or C 1-5  alkoxy groups and A is a hydrogen or halogen atom or a hydroxy, C 1-5  alkyl or C 1-5  alkoxy group, and addition salts thereof with mineral and organic bases are prepared by reaction of a haloacetylbenzoic acid of the general formula wherein X is a chlorine or bromine atom, with a thioamide of the general formula followed optionally by salification of the product, Pharmaceutical compositions having valuable properties with regard to fibrinolysis, platelet stickiness, ulcer and immunological processes comprise, as active ingredient, a thiazolylbenzoic acid of the first general formula above or a physiologically tolerable addition salt thereof with a suitable mineral or organic base, together with a pharmaceutically suitable carrier, and may be administered orally, rectally or parenterally.
INTRODUCTION: Small fiber neuropathy (SFN) is a common cause of neuropathic pain in peripheral neuropathies. Good accessibility of diagnostics and treatment is necessary for an accurate diagnosis and treatment of SFN. Evidence is lacking on the quality performance of the diagnostic SFN service in the Netherlands. Our aim was to determine the patient satisfaction and -accessibility of the diagnostic SFN service, and to identify areas for improvement.
METHODS: In a single-center, prospective, survey-based cohort study, 100 visiting patients were asked to fill in the SFN patient satisfaction questionnaire (SFN-PSQ), with 10 domains and 51 items. Cut-off point for improvement was defined as ≥ 25% dissatisfaction on an item. A chi-square test and linear regression analyses was used for significant differences and associations of patient satisfaction.
RESULTS: From November 2020 to May 2021, 98 patients with SFN-related complaints filled in the online SFN-PSQ within 20 minutes. In 84% of the patients SFN was confirmed, average age was 55.1 (52.5-57.8) years and 67% was female. High satisfaction was seen in the domains 'Waiting List Period', Chest X-ray', 'Consultation with the Doctor or Nurse Practitioner (NP)', 'Separate Consultation with the Doctor or NP about Psychological Symptoms', and 'General' of the SFN service. Overall average patient satisfaction score was 8.7 (IQR 8-10) on a 1-to-10 rating scale. Main area for improvement was shortening the 8-week period for receiving the results of the diagnostic testing (p < 0.05). General health status was statistically significant associated with patient satisfaction (p < 0.05).
CONCLUSION: A good reflection of the high patient satisfaction and -accessibility of the SFN-service is shown, with important points for improvement. These results could help hospitals widely to optimize the logistic and diagnostic pathway of SFN analysis, benchmarking patient satisfaction results among the hospitals, and to improve the quality of care of comparable SFN services.
Two researchers will read all the peer-review reports and editors' comments for the first round. The researchers will determine whether the peer-reviewers and/or editors raised some concern on the completeness of reporting of the 10 CONSORT items considered and identified a switch primary outcome(s) between the manuscript and the register. The assessment of all peer-review reports and editors' comments for each manuscript will be combined (i.e., the item will be rated as incompletely reported if at least one peer reviewer rated it as such). The 2 researchers will be blinded to the gold standard assessment.